These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 23139820)

  • 21. A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer.
    Zhang KQ; Yang F; Ye J; Jiang M; Liu Y; Jin FS; Wu YZ
    Urology; 2012 Jun; 79(6):1410.e7-13. PubMed ID: 22513035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human prostate stem cell antigen and HSP70 fusion protein vaccine inhibits prostate stem cell antigen-expressing tumor growth in mice.
    Dong L; Zhang X; Ren J; Wu S; Yu T; Hou L; Fu L; Yi S; Yu C
    Cancer Biother Radiopharm; 2013 Jun; 28(5):391-7. PubMed ID: 23701419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
    Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
    Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.
    Odegard JM; Kelley-Clarke B; Tareen SU; Campbell DJ; Flynn PA; Nicolai CJ; Slough MM; Vin CD; McGowan PJ; Nelson LT; Ter Meulen J; Dubensky TW; Robbins SH
    J Immunother; 2015; 38(2):41-53. PubMed ID: 25658613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
    Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R
    Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen.
    Cole G; Ali AA; McErlean E; Mulholland EJ; Short A; McCrudden CM; McCaffrey J; Robson T; Kett VL; Coulter JA; Dunne NJ; Donnelly RF; McCarthy HO
    Acta Biomater; 2019 Sep; 96():480-490. PubMed ID: 31299353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
    Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
    Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
    Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
    Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses.
    Lopes L; Dewannieux M; Gileadi U; Bailey R; Ikeda Y; Whittaker C; Collin MP; Cerundolo V; Tomihari M; Ariizumi K; Collins MK
    J Virol; 2008 Jan; 82(1):86-95. PubMed ID: 17959670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
    Liu Y; Peng Y; Mi M; Guevara-Patino J; Munn DH; Fu N; He Y
    J Immunol; 2009 May; 182(10):5960-9. PubMed ID: 19414747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
    Hesse C; Ginter W; Förg T; Mayer CT; Baru AM; Arnold-Schrauf C; Unger WW; Kalay H; van Kooyk Y; Berod L; Sparwasser T
    Eur J Immunol; 2013 Oct; 43(10):2543-53. PubMed ID: 23784881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
    J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer.
    Guo C; Yi H; Yu X; Zuo D; Qian J; Yang G; Foster BA; Subjeck JR; Sun X; Mikkelsen RB; Fisher PB; Wang XY
    Mol Cancer Ther; 2012 Nov; 11(11):2331-41. PubMed ID: 22896667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
    Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
    Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells.
    Feldmann A; Arndt C; Töpfer K; Stamova S; Krone F; Cartellieri M; Koristka S; Michalk I; Lindemann D; Schmitz M; Temme A; Bornhäuser M; Ehninger G; Bachmann M
    J Immunol; 2012 Sep; 189(6):3249-59. PubMed ID: 22875801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.